| |
Antibodies are a crucial reagent in R&D, diagnostics, & therapeutics. Download the eBook to learn how you can apply custom antibodies in your work.
|
|
Today's Big NewsDec 16, 2022 |
| By Eric Sagonowsky With its second approval in as many months, Ferring Pharmaceuticals is celebrating a fruitful end to 2022. |
|
|
|
By James Waldron For years, Alexion has been the only name in the game for a blood disease called paroxysmal nocturnal hemoglobinuria. Now, a number of Big Pharmas want in. |
By Paige Minemyer Centene CEO Sarah London is continuing to build out the insurer's leadership team. London was tapped to succeed longtime CEO Michael Neidorff in March. |
By Andrea Park Medtronic laid out the plans to spin off its patient monitoring and respiratory interventions businesses into a combined company in late October. |
|
If the clinical supply chain is poorly managed, sponsors can struggle to cope with the complexities, causing issues. This playbook covers keys to identifying the need to implement an eClinical Supply Chain Management platform. Download now.
|
|
By Zoey Becker Top industry trade groups will be continuing on without pharma powerhouse AbbVie. The company quietly departed from the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO), plus the Business Roundtable, Politico first reported. |
By Teresa Carey This week on “The Top Line,” we discuss the medtech industry’s highest paid CEOs. Plus, we cover Theranos' COO's prison sentence, highlights from the American Society of Hematology annual meeting and other top headlines from this week. |
By Andrea Park The QmTriage software takes in standard 2D mammograms to look for potential signs of cancer. If any are found, the system labels them and automatically flags the scan for closer review by a human radiologist. |
By Max Bayer Alnylam has elected to cull three clinical-stage programs, including an IgA nephropathy med once-partnered with Regeneron that was headed for a phase 3 trial. Alnylam said that Regeneron pulled out of the program, prompting a reassessment of development plans. |
By Annie Burky ElliQ, the first proactive AI care companion and Time Best Invention of 2022, is getting an update with 2.0 hardware and software along with the new addition of a caregiver app in order to further address the senior loneliness epidemic. |
By James Waldron If Astellas needed further proof that its $1.3 billion oncology bet was worth the price tag, the second successful phase 3 trial in a month should do the trick. |
By James Waldron Eli Lilly has followed in the footsteps of many Big Pharma contemporaries by penning its own $730 million deal with Sosei Heptares to work on new meds that modulate G protein-coupled receptor (GPCR) targets. |
By Dave Muoio "Inflammatory" posts from influential social media users regularly escalate to offline threats that are forcing providers to limit gender-affirming services or resources, according to a new report from an LGBTQ+ civil rights organization. |
By Kevin Dunleavy A federal court in West Virginia has upheld AstraZeneca's claim of infringement against Viatris and Kindeva. With the win, AZ gains six more months of exclusivity for asthma inhaler Symbicort, which generated (PDF) $2.7 billion in sales in 2021. |
Fierce podcastsDon't miss an episode |
| This week on “The Top Line,” we discuss the medtech industry’s highest paid CEOs. Plus, we cover Theranos' COO's prison sentence, highlights from the American Society of Hematology annual meeting and other top headlines from this week. |
|
|---|
|
|
|
Wednesday, January 25, 2023 | 11am ET / 8am PT This webinar, presented by AmerisourceBergen, will deliver insights to manufacturers and payers covering the need for education and best practices for increasing biosimilar adoption, current product landscape and upcoming product launches, and more. Register now.
|
|
| VideoRevolutionize your monoclonal antibody (mAb) manufacturing with expert insights. Sponsored by: Gibco |
| WhitepaperLearn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
| Executive Summary Strategies to help scale-up for commercial manufacturing are critical to getting cell and gene therapies to patients as more advanced therapies reach late-stage clinical studies and regulatory decisions. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| |
|
